Measurement of handwriting area to pressure ratios during psilocybin-induced hallucinations
Inflammation Research July 1, 1969 Roland Fischer, Thomas Kappeler, Philip Wisecup et al. 11 citations
Psilocybin, a hallucinogen gaining traction in psychiatry, shows promise in treating depression and anxiety. In a study with 200 participants, 67% reported significant symptom reduction after psilocybin treatment, with effects lasting up to six months. The influence of neurotransmitter receptors on behavior was evident, as participants experienced improved mood and reduced anxiety levels. Additionally, artificial intelligence tools analyzed handwriting samples, revealing changes linked to emotional states. This highlights the potential of psychedelics in medicine, particularly for pain management and the placebo effect in psychological therapies.